Vaccines News and Research RSS Feed - Vaccines News and Research

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe. [More]
Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014. [More]
NIH to begin trials for experimental Ebola vaccine

NIH to begin trials for experimental Ebola vaccine

The announcement about the testing comes as the outbreak in West Africa grows. The World Health Organizations says it could have infected more than 20,000 people. [More]
Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa. [More]
NIH to start initial human testing of investigational Ebola vaccine next week

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide. [More]
Researcher finds income, education disparity in reasons for not vaccinating

Researcher finds income, education disparity in reasons for not vaccinating

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may not be fully vaccinated depends on the class privilege of their mothers. [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]
Expanding age of eligibility for measles vaccination could have large effects on coverage in Africa

Expanding age of eligibility for measles vaccination could have large effects on coverage in Africa

Expanding the age of eligibility for measles vaccination from 12 to 15 months could have potentially large effects on coverage in Africa, according to a new report published by Princeton University's Woodrow Wilson School of Public and International Affairs. [More]
State highlights: Minn. vaccine requirements; Sovaldi in Calif. prisons; Ga. Rural ERs

State highlights: Minn. vaccine requirements; Sovaldi in Calif. prisons; Ga. Rural ERs

For the first time in a decade, Minnesota schoolchildren are required to receive additional vaccines this fall. Seventh-graders now must get the meningococcal vaccination and an additional pertussis (whooping cough) booster. [More]
Insight could lead to new and better drugs

Insight could lead to new and better drugs

There's a certain type of biomolecule built like a nano-Christmas tree. Called a glycoconjugate, it's many branches are bedecked with sugary ornaments. [More]
BD announces winners of 2014 "Innovations in Care" awards

BD announces winners of 2014 "Innovations in Care" awards

BD (Becton, Dickinson and Company), a leading global medical technology company – together with Direct Relief and the National Association of Community Health Centers – has announced the winners of the 2014 "Innovations in Care" awards to seven community health centers as part of the BD Helping Build Healthy CommunitiesSM initiative. [More]
UAB scientist receives R01 grant to study transmission of deadly bacteria from mothers to infants

UAB scientist receives R01 grant to study transmission of deadly bacteria from mothers to infants

New research from the University of Alabama at Birmingham School of Optometry will study the transmission of a bacteria that up to 40 percent of healthy women carry, which becomes deadly when passed on to infants during birth. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]
Newborn screening for SCID holds promise that affected children can lead healthy lives

Newborn screening for SCID holds promise that affected children can lead healthy lives

Using population-based screening outcomes of approximately 3 million infants, a team of scientists across 14 states, including four researchers at the University of Massachusetts Medical School, have shown that newborn screening for severe combined immunodeficiency (SCID) can be successfully implemented across public health newborn screening programs. [More]
OMRF receives $14.5 million grant from NIH to continue research on anthrax

OMRF receives $14.5 million grant from NIH to continue research on anthrax

The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a five-year, $14.5 million grant to continue its research on anthrax and the bacteria's effects on humans. [More]
Five tips to make children go back to school

Five tips to make children go back to school

It's that time of year again: parents are winding down summer plans and tightening the reins on bedtime schedules. And while adding anything else to the back-to-school to-do list may seem daunting, Children's Memorial Hermann Hospital has five tips that will make going back to school this year easier than ever. [More]
Newborn screening indicates that incidence of SCID is higher than previously believed

Newborn screening indicates that incidence of SCID is higher than previously believed

Newborn screening performed in numerous states indicates that the incidence of the potentially life-threatening disorder, severe combined immunodeficiency, is higher than previously believed, at 1 in 58,000 births, although there is a high rate of survival, according to a study in the August 20 issue of JAMA. [More]